BUZZ - Edwards Lifesciences shares rise after raising 2026 profit outlook
路透社2026/11/04 22:32November 4 - ** Edwards Lifesciences Corporation (EW.N) shares rose 3.7% in after-hours trading to $103.05
** Raised its annual adjusted earnings per share forecast from $2.95–3.05 to $2.97–3.05, representing an 18% year-on-year increase at the midpoint
** Increased its 2026 company sales growth outlook from 10%–11% to about 11.5%
** According to data compiled by London Stock Exchange Group (LSEG), the company’s third-quarter sales grew 10.5% year-on-year to $1.72 billion, above analysts' expectations of $1.67 billion
** As of the previous trading day's close, the stock had gained 16.6% cumulatively this year
(To assist non-English speakers, Reuters provides reports automatically translated into several other languages. Automated translations may contain errors or may fail to capture the needed context; Reuters does not guarantee the accuracy of translated texts, which are provided solely for readers' convenience. Reuters accepts no liability for any damage or loss arising from the use of this automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Tandem Diabetes Care appoints Janet Banks as CEO, shares rise
South Korea denies considering large-scale purchases of long-term U.S. Treasury bonds, stating that Korean media reports are inconsistent with the facts.
The Ministry of Economy and Finance of South Korea and the Bank of Korea (BOK) issued a joint statement refuting a local media report. The report had claimed that, in response to significant foreign capital outflows, Seoul was considering purchasing a large amount of U.S. government bonds. Both institutions emphasized that the composition and specific details regarding the management of South Korea's foreign exchange reserve assets are not disclosed to the public.


BUZZ-Solventum shares fall after reporting a decline in third-quarter sales